Modifications To Cas9 For Passive-Delivery Into Cells

Tech ID: 25286 / UC Case 2016-016-0

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 11,118,194 09/14/2021 2016-016

Brief Description

RNA-mediated adaptive immune systems in bacteria and archaea rely on Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) genomic loci and CRISPR-associated (Cas) proteins that function together to provide protection from invading viruses and plasmids. In Type II CRISPR-Cas systems, the Cas9 protein functions as an RNA-guided endonuclease that uses a dual-guide RNA consisting of crRNA and trans-activating crRNA (tracrRNA) for target recognition and cleavage by a mechanism involving two nuclease active sites that together generate double-stranded DNA breaks (DSBs). Thus, the Cas9 system provides a facile means of modifying genomic information.


UC Berkeley researchers have developed modified site-directed modifying polypeptides and ribonucleoproteins comprising the modified polypeptides. As the modified site-directed modifying polypeptides are modified for passive entry into target cells, the polypeptides are useful in a variety of methods for target nucleic acid modification.


Suggested uses

  • Genome editing
  • Gene therapy



  • Crosses the plasma membrane of a eukaryotic cell without the need for any additional agent (e.g., small molecule agents, lipids, etc.)


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Doudna, Jennifer A.

Other Information


CRISPR, Cas9, gene, genome editing

Categorized As

Additional Technologies by these Inventors